<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Enalapril improves outcome in asymptomatic LV dysfunction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Enalapril improves outcome in asymptomatic LV dysfunction</h1>
<div class="graphic"><div class="figure"><div class="ttl">Enalapril improves outcome in asymptomatic LV dysfunction</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">In the SOLVD prevention trial of 4228 patients (83 percent post-MI) with asymptomatic left ventricular dysfunction, prophylactic administration of enalapril reduced the probability of death or heart failure (p&lt;0.001).</div><div class="graphic_footnotes">ACE: angiotensin-converting enzyme; LV: left ventricular; MI: myocardial infarction.</div><div class="graphic_reference">Data from: The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685.</div><div id="graphicVersion">Graphic 75136 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
